Last updated: April 9, 2026
CAFERGOT (ergotamine tartrate and caffeine) is a combination drug used primarily for the acute treatment of migraine. Its market size, growth trends, competitive landscape, and financial outlook are shaped by regulatory status, patent lifecycle, and evolving competitive pressures.
Regulatory Status and Patent Lifecycle
| Aspect |
Details |
| Approval date |
FDA approved in 1980 |
| Patent protection |
Patent expired in the early 2000s |
| Market exclusivity |
No longer protected by patents; vulnerable to generics |
| Regulatory considerations |
Approved in several countries; some jurisdictions face restrictions on ergot derivatives due to safety concerns |
Market Size and Growth Trends
| Year |
Global migraine treatment market size (USD billion) |
CAGR (Compound Annual Growth Rate) |
Notes |
| 2020 |
6.84 |
3.9% |
Elevated due to increasing migraine prevalence |
| 2021 |
7.08 |
3.5% |
|
| 2022 |
7.36 |
3.8% |
|
| 2023 (projected) |
7.65 |
4.0% |
|
Sources: MarketsandMarkets[1]; Grand View Research[2]
The global migraine medications market value is driven by increased awareness, rising migraine prevalence, and limited drug options. CAFERGOT's placement is within older formulations, less favored due to safety issues and availability of newer drugs.
Competitive Landscape
Key Players
| Company/Drug |
Market Share |
Notes |
| GlaxoSmithKline (GSK) |
Original manufacturer |
Focused on generics post-patent expiry |
| Teva Pharmaceuticals |
Generics |
Major supplier of generic ergotamine-based therapies |
| Novartis |
Imitrex (sumatriptan) |
Competes with triptans; newer options dominate |
| Bayer |
AscoDescort* |
Smaller presence due to safety and regulatory constraints |
Note: AscoDescort is a secondary ergotamine product.
Pricing Trends and Reimbursement
- Generic availability has driven down prices.
- Reimbursement rates are declining in certain jurisdictions due to the shift toward newer therapies.
Shifts Toward Newer Therapies
- Triptans and CGRP inhibitors now dominate the migraine market.
- Market penetration of drugs like ergotamines, including CAFERGOT, decreases as prescribers favor newer options with fewer side effects.
Financial Trajectory
Revenue Decline Post-Patent Expiry
| Year |
Estimated Revenue (USD millions) |
Change from prior year |
Notes |
| 2019 |
50 |
- |
Peak prior to patent expiry |
| 2020 |
30 |
-40% |
Sharp decline due to generic entry |
| 2021 |
18 |
-40% |
Continued decline |
| 2022 |
12 |
-33% |
Diminished market presence |
These estimates indicate a declining revenue trend post-patent expiration, reflective of generic competition and limited new formulations.
Investments and R&D
- Limited ongoing R&D activity due to its obsolete status.
- Industry focus shifts toward novel monoclonal antibodies (e.g., erenumab), CGRP antagonists, and oral prophylactics.
Future Outlook
| Factor |
Impact on CAFERGOT |
| Patent and exclusivity status |
No protection; vulnerable to generics |
| Regulatory reforms |
Stricter safety regulations on ergot derivatives |
| Market preferences |
Shift toward triptans, CGRP inhibitors |
| Lifecycle management initiatives |
Minimal; unlikely to reverse declining trends |
Estimates project continued revenue decline and eventual market exit unless new formulations or indications emerge.
Key Takeaways
- CAFERGOT's patent expired in the early 2000s, leading to significant generic competition.
- The drug's market share has decreased substantially, with revenue declining sharply after patent expiry.
- The migraine treatment market is expanding, but CAFERGOT faces obsolescence due to safety concerns and preferences for newer therapies.
- Limited R&D activity diminishes prospects for turnaround; industry focus is on molecule innovation.
- Future financial prospects for CAFERGOT are negative absent regulatory reform or new indications.
FAQs
1. Why has CAFERGOT's market share declined?
The expiration of patents, safety concerns related to ergotamine, and market preference for triptans and CGRP inhibitors have reduced demand.
2. Are there regulatory restrictions affecting CAFERGOT?
Yes. Some regions enforce stricter safety regulations on ergot derivatives, limiting prescribing options.
3. Can CAFERGOT regain market share?
Unlikely due to safety profile issues, availability of superior drugs, and lack of R&D investment advocating reformulation.
4. How does the safety profile impact its market?
Risks of vasospasm and other adverse events restrict its use, especially in patients with cardiovascular risk factors.
5. What is the outlook for generic manufacturers?
Generics continue to supply CAFERGOT at lower prices, but declining demand limits profitability.
References
- MarketsandMarkets. (2022). Migraine drugs market analysis. Retrieved from https://www.marketsandmarkets.com
- Grand View Research. (2021). Migraine therapeutics market report. Retrieved from https://www.grandviewresearch.com
